קונבריזה

Country: Израел

Језик: Хебрејски

Извор: Ministry of Health

Активни састојак:

BAZEDOXIFENE AS ACETATE 20 MG

Доступно од:

NEOPHARM LTD

АТЦ код:

G03XC02

Фармацеутски облик:

COATED TABLETS

Пут администрације:

PER OS

Произведен од:

PFIZER IRELAND PHARMACEUTICALS

Терапеутска група:

BAZEDOXIFENE

Терапеутске индикације:

CONBRIZA is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established. When determining the choice of CONBRIZA or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefit

Датум одобрења:

2013-04-01